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Despite an urgent clinical need for small caliber
(4 mm or smaller) prosthetic grafts, their use has
been limited because of their relatively low patency
rates. The thrombotic propensity of these grafts
plays a critical role in their graft patency.1 Prosthetic
grafts have been developed with vascular endothelial
cells (ECs) seeded onto their luminal surface to
overcome this problem.2 ECs can produce
antithrombotic agents, such as tissue-type plasmino-
gen activator (tPA), thrombomodulin, and heparan
sulfate, and EC-seeded grafts have shown better
early patency in animal models than nonseeded
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Purpose: Seeding a prosthetic graft with genetically engineered vascular endothelial cells
(ECs) has the potential to enhance the graft’s antithrombotic properties. However, it
has been reported that ECs transduced with tissue-type plasminogen activator (tPA)
have very low levels of retention on grafts, probably because of increased proteolytic
activity. We examined the retention of human tPA (htPA)-transduced ECs after the cells
were seeded onto expanded polytetrafluoroethylene (ePTFE) grafts and implanted into
dogs. We also examined the function of secreted htPA in this model.
Methods and Results: Canine jugular venous ECs were transduced with adenoviral vectors
encoding htPA (Adex1CAhtPA) and β-galactosidase (Adex1CALacZ). There was a pos-
itive relationship between the percentage of X-gal ECs staining and the multiplicity of
infection (MOI) of Adex1CALacZ. The level of htPA production in vitro increased with
the increasing MOI of Adex1CAhtPA, but decreased gradually 4 days after infection.
ECs coinfected with Adex1CAhtPA and Adex1CALacZ (htPAEC) or ECs infected with
Adex1CALacZ alone (LacZEC) were seeded onto ePTFE grafts at densities equivalent
to confluence to visualize retained ECs in an in vivo flow study. The grafts were implant-
ed into canine carotid arteries and harvested after 5 hours of exposure to blood flow.
The harvested grafts showed patchy defects in ECs, most of which were covered with
mural thrombi. There was no significant difference in retention between htPAEC
(29.3% ± 8.7%) and LacZEC (19.5% ± 3.6%). There was a significant negative correla-
tion between the in vivo EC retention on the grafts and the in vitro cellular passage level
of ECs (P = .041; r = –.40). htPAEC produced 210.3 ± 22.2 ng htPA antigen/106 cells
per 6 hours in vitro and continued to secrete htPA on the harvested graft. 
Conclusions: We demonstrated that a large amount of functional htPA was produced by
adenovirally modified canine ECs. The results of the in vivo study may suggest that over-
expression of tPA has little effect on the short-term retention of early passage ECs seed-
ed onto ePTFE grafts. (J Vasc Surg 2000;32:353-63.)
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grafts.3-5 Although human clinical trials in this area
have been ongoing,6 the improved patency of small-
caliber prosthetic grafts seeded with autogenous
ECs has yet to be proved in humans.
Recently, gene transfer techniques have made it
possible to genetically increase the antithrombotic
function of ECs.7-11 One of the strategies to amelio-
rate the effects of EC seeding involves the introduc-
tion of the tPA gene to ECs that cover the graft sur-
face. Dichek et al8-12 demonstrated that sheep ECs,
retrovirally transduced with the human tPA (htPA)
gene, enhanced cellular fibrinolytic activity both in
vitro and in vivo and produced a 10-fold higher level
of htPA than nontransduced human ECs. In our lab-
oratory, we have succeeded in introducing the htPA
gene into human ECs by using an adenoviral vec-
tor.10 In vitro, these transduced ECs produce 830
times the amount of functional htPA, as compared
with nontransduced ECs.
Human tPA-transduced ECs are reported to be
retained at a low level, both in vitro and in vivo, after
being seeded onto grafts.13 It has been suggested
that the decreased rate of cell retention could be
attributed mainly to increased proteolytic activity of
the htPA-transduced ECs.13 In contrast, the results
of our recent in vitro study showed no significant dif-
ference in cell retention among adenovirally htPA-
transduced, β-galactosidase (LacZ)-transduced, and
nontransduced human ECs, although the htPA activ-
ity of our adenovirally transduced human ECs was
more than 10,000 times that of nontransduced
human ECs.10
In the current study, we examined the level of
htPA production by adenovirally htPA-transduced
ECs in vitro and EC retention in vivo on expanded
polytetrafluoroethylene (ePTFE) grafts in a canine
model.
METHODS
Harvest and culture of endothelial cells.
Vascular ECs were harvested from adult outbred
dogs that weighed 15 to 22 kg. General anesthesia
was induced with an intramuscular injection of keta-
mine hydrochloride (16 mg/kg) and was main-
tained with an intravenous injection of pentobarbital
sodium (10 mg/kg). With aseptic techniques, a 5-
cm segment of the external jugular vein was
exposed, everted on a Pasteur pipette, and trans-
ferred to the laboratory in chilled Hank’s balanced
salt solution without Ca2+ or Mg2+ (HBSS–;
GIBCO, Grand Island, NY).
The segment of vein was digested at 37°C for 13
minutes in a solution of 0.1% type-II collagenase
(Worthington, Malvern, Pa) in HBSS- supplement-
ed with 0.1% bovine serum albumin (Sigma, St
Louis, Mo). The vein was flushed four times with 10
mL M-199 tissue culture medium (GIBCO), and
ECs were harvested by means of centrifugation at
1000 rpm for 10 minutes.
ECs were suspended in 10 mL M-199 culture
medium supplemented with 25 mmol/L 4-(2-
hydroxyethyl)-1-piperazine ethanesulfonic acid
(HEPES), 20% fetal bovine serum (Hyclone, Logan,
Utah), 0.7 mmol/L L-glutamine, 17.5 U/mL
porcine intestinal mucosa-derived heparin (Sigma),
20 µg/mL EC mitogen (Biomedical Technologies,
Stoughton, Mass), 50 U/mL penicillin G sodium,
50 µg/mL streptomycin sulfate, and 125 ng/mL
amphotericin B (GIBCO), and incubated in colla-
gen-coated culture plates (25 cm2, Falcon, Becton
Dickinson Labware, Lincoln Park, NJ) at 37°C in a
5% CO2 environment. The culture medium was
changed three times a week. When the cells reached
confluence, they were passaged by digestion with
0.05% trypsin plus 0.01% ethylenediaminetetraacetic
acid (EDTA; GIBCO) in HBSS–.
EC identity was established by means of positive
staining for von Willebrand factor antigen (Atlantic
Antibodies, Scarborough, Me). In addition, immuno-
histochemical staining with a mouse monoclonal 
antibody specific for the α- and γ-actin isoforms of
muscle (HHF 35; Enzo Biochemicals, New York,
NY) was performed as a means of precluding the 
possibility of smooth muscle cell contamination of the
culture.
Adenoviral vectors encoding human tissue-type
plasminogen activator and β-galactosidase genes.
The recombinant adenoviruses, Adex1CAhtPA and
Adex1CALacZ (which encode the htPA and reporter
Escherichia coli β-galactosidase [LacZ] genes, respec-
tively), were constructed by means of homologous
recombination of the expression cosmid cassette with
the parental viral genome, as previously described.10
The recombinant viral vectors were stored at –80°C.
The viral titers for the recombinant vectors were both
determined to be 3.99109 plaque forming units
(pfu)/mL by using a plaque assay with 293 cells.14
Evaluation of human tissue-type plasminogen
activator and β-galactosidase gene expression in
vitro. In six-well culture plates (3.5-cm diameter
wells), fully confluent canine ECs were exposed to
various concentrations of the recombinant ade-
novirus. The multiplicity of infection (MOI) was
defined as the ratio of vector molecules to target
cells at the time of infection (pfu/cell). Endothelial
cells were incubated for 1 hour in viral solutions at
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Fig 1. A, The effect of the multiplicity of infection (MOI) on the proportion of stained cells after
infection with Adex1CALacZ. Endothelial cells were stained after infection with Adex1CALacZ at an
MOI of 0, 30, 100, 300, 500, and 1000, as described in the Methods section. A positive correlation
was observed between the proportion of stained cells and the MOI of Adex1CALacZ. Each point rep-
resents the mean plus or minus the SEM of triplicate assays. B and C, The effect of MOI on secreted
human tissue-type plasminogen activator (htPA) antigen (B) and activity (C) after infection with
Adex1CAhtPA. Endothelial cells were infected with Adex1CAhtPA at an MOI of 0, 10, 50, 100, 500,
and 1000, and the secreted htPA antigen and htPA activity were measured as described in the Methods
section. A positive correlation was observed between htPA antigen or htPA activity and the MOI of
Adex1CAhtPA. Each point represents the mean plus or minus the SEM of triplicate assays. D, The
effect of incubation time on htPA secretion after endothelial cell infection with Adex1CAhtPA.
Endothelial cells were infected with Adex1CAhtPA for 1 hour at an MOI of 500. Endothelial cell den-
sity and the amount of htPA antigen produced were estimated 0, 2, 4, 7, 14, and 21 days after infec-
tion. The amount of htPA antigen produced by endothelial cells reached more than 200 ng/106 cells
per 6 hours by day 4 after infection, but dropped significantly on the seventh day, and declined there-
after. Each point represents the mean plus or minus the SEM of triplicate assays.
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various MOI, and after infection, the viral solution
was replaced with the regular culture medium. After
an additional 48 hours of incubation at 37°C, gene
expression was analyzed.
After being fixed in 0.5% glutaraldehyde for 5
minutes and rinsed with phosphate-buffered saline
(PBS), the Adex1CALacZ-infected cells were
immersed for 6 hours in PBS containing 5 mmol/L
potassium ferrocyanide, 5 mmol/L potassium ferri-
cyanide, 2 mmol/L magnesium chloride, and 1
mmol/L 5-bromo-4-chloro-3-indolyl-β-D-galac-
topyranoside (X-gal). The surface of each well con-
taining Adex1CALacZ-infected cells was then exam-
ined by means of bright-field microscopy. With the
aid of a reticule inserted into the microscope’s ocular
lens, which outlined 1 mm2 of the well surface, total
and blue (X-gal–stained) cell counts (cell/mm2)
were performed for five representative fields per well.
These counts were then averaged to determine the
total number of cells and the number of X-
gal–stained cells present on the plate. The transduc-
tion efficiency was calculated by dividing the number
of X-gal–stained cells by the total cell number.
Adex1CAhtPA-infected ECs were incubated for
6 hours in 1 mL fresh culture. The concentration of
htPA antigen in the medium was then measured by
using an enzyme-linked immunosorbent assay
(ELISA; Imulyse tPA Test kit, Biopool, Umea,
Sweden), and htPA activity was determined by using
the Spectrolyse Fibrin Test kit (Biopool). After
trypsinization and suspension in Isoton II solution,
the number of ECs was determined by using an elec-
trical cell counter (Coulter Electronics, Hialeah,
Fla), and the cell density was calculated by dividing
the cell number by the area of the well.
Confluent ECs were infected with Adex1CAhtPA
at an MOI of 500 for 1 hour to determine the dura-
tion of maximal htPA secretion from the htPA-trans-
duced ECs. After incubation for 2, 4, 7, 14, and 21
days, the number of ECs in the wells was counted,
and the amount of htPA secreted into the medium
was quantified.
Northern blot analysis. ECs cultured on a 10-
cm–diameter culture plate were exposed for 1 hour
to solutions containing either Adex1CAhtPA or
Adex1CALacZ at an MOI of 500. After 48 hours of
incubation in the culture medium, total RNA was
isolated from ECs by means of acid guanidinium
thiocyanate-phenol-chloroform extraction.15 RNA
was electrophoresed through a formalin-1% agarose
gel and blotted onto a Hybond-N nylon membrane
(Amersham, Buckinghamshire, UK). Radiolabeled
XhoI and XbaI fragments (approximately 2.5 kb)
from tPAEV37 (provided by Dr N. Hoda, Research
Institute of Life Science, Snow Brand Milk
Products, Tochigi, Japan) were used to probe for the
htPA gene. The membrane was stripped and re-
probed with β-actin to control for the amount of
RNA loaded.
Endothelial cell seeding on graft. ECs were
passaged between three and six times before use in
the following experiments. ECs were simultaneously
infected with Adex1CAhtPA and Adex1CALacZ
(htPAEC), each at an MOI of 500, to visualize tPA-
transduced cells. As a control, ECs were infected
with Adex1CALacZ (LacZEC) at an MOI equiva-
lent to that of htPAEC (ie, an MOI of 1000). The
cells were trypsinized 24 hours after infection and
suspended in culture medium at a concentration of
106 cells/mL.
ePTFE vascular grafts, 7 cm in length and 4 mm
in diameter (provided by Impra, Tempe, Ariz), were
filled with PBS supplemented with 50 µg/mL dis-
solved human fibronectin (Boehringer-Mannheim,
Indianapolis, Ind). Both ends were occluded with
plastic caps, and the grafts were incubated for 1 hour
at 37°C. After removal of the fibronectin solution, the
cell suspensions were introduced to the grafts. The
grafts (maintained in a horizontal position) were
rotated along their axial plane at 6 revolutions per
hour for 90 minutes at 37°C, and then immersed in
culture medium for 24 hours in a CO2 incubator. Just
before implantation, part of each seeded graft was
taken for X-gal staining as a means of determining the
preoperative cell density. At the time of EC seeding,
some of the infected cells (ie, enough cells to fully
cover the surface of a well in a six-well plate) were
replated into a six-well plate for htPA measurement.
In vivo flow studies. Grafts 5 cm in length and
seeded with autologous ECs were implanted into the
carotid arteries of eight dogs. The dogs, weighing
19.1 ± 0.5 kg, were given an intramuscular injection
of ketamine hydrochloride (16 mg/kg) for induction
of anesthesia and intravenous pentobarbital sodium
(10 mg/kg) for anesthesia maintenance. Heparin
sodium (100 U/kg) was injected intravenously before
graft implantation. The grafts were anastomosed to
the carotid artery in an end-to-side fashion with a
running 6-0 monofilament polypropylene suture.
After the completion of anastomosis, each artery was
divided between the proximal and the distal anasto-
moses, and blood flow was reestablished. A graft seed-
ed with htPAEC was implanted on one side, and a
control graft seeded with LacZEC was implanted on
the other.
The grafts were harvested after 5 hours of expo-
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sure to blood flow. A 1-cm segment of the harvested
graft was incubated for 6 hours in 1 mL culture medi-
um at 37°C as a means of evaluating the amount of
htPA secreted from the graft. The remaining segment
was used for X-gal staining as a means of evaluating
the cell density after exposure to blood flow. The test
and control grafts were fixed in 0.5% glutaraldehyde
in PBS for 5 minutes, rinsed with PBS, and incubated
in X-gal solution at 37°C for 6 hours. The grafts were
then opened longitudinally, and the graft surface was
examined by means of bright-field microscopy. Each
graft was divided into four areas according to cell den-
sity. The size of each area (mm2) was calculated, and
an in situ cell count (cell/mm2) was performed for
three representative fields per area. For the average
cell density (cell/mm2) on the surface of each graft to
be determined, cell counts obtained for each area
were averaged, and the sum of the averaged cell
counts multiplied by the size of each area was divided
by the total area of the graft. The percentage of ECs
retained on the seeded graft was then calculated by
dividing the averaged cell density of the harvested
graft by the averaged cell density of the graft before
implantation and multiplying by 100.
The blood flow of the carotid artery distal to the
anastomoses was measured before graft implanta-
tion, immediately after graft implantation, and
immediately before graft harvest, by using an
Ultrasonic Transit-time Flowmeter HT 207
(Transonic Systems, New York, NY). Blood samples
were taken from each dog before graft implantation
and during graft harvesting and were evaluated for
plasma levels of fibrinogen and htPA antigen.
Statistical analysis. htPA secretion and activity
and the cell retention data are expressed as the mean
plus or minus the SEM and were analyzed by using
the Student t test for unpaired samples. Analysis of
the cell passage level versus the cell retention level
was performed by using the Spearman rank correla-
tion. Statistical significance was assumed when the P
value was less than .05.
Experimental approval. All experimental proce-
dures were performed in compliance with the poli-
cies of the University of Tokyo and the standards of
“The Guide for the Care and Use of Laboratory
Animals” (NIH publication 85-23; 1985) estab-
lished by the American Physiological Society and the
National Institutes of Health.
RESULTS
In vitro transduction efficiency of human 
tissue-type plasminogen activator and β-galac-
tosidase secretion from human tissue-type plas-
minogen activator-transduced endothelial cells at
various multiplicities of infection. The proportion
of X-gal–stained ECs after infection with
Adex1CALacZ (at MOI of 0, 30,100, 300, 500, and
1000) and exposure to X-gal is shown in Fig 1, A.
The proportion of stained cells showed a positive
correlation with the MOI of the recombinant virus
at an MOI as high as 500. At an MOI of 500 and
and MOI of 1000, 46.0% ± 14.1% and 74.9% ± 2.8%
of the cells were stained, respectively. No significant
difference was seen in total cell density at the various
MOI (data not shown).
The level of htPA antigen and htPA activity of ECs
infected with Adex1CAhtPA (at MOI 0 to 1000) are
shown in Fig 1, B and C, respectively. Both htPA anti-
gen and activity levels showed a positive correlation
with the MOI of the recombinant adenoviral vectors,
whereas there was only a small difference in htPA anti-
gen and activity levels at an MOI between 500 and
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Fig 2. Northern blot analysis of human tissue-type plas-
minogen activator (tPA) messenger RNA. The total RNA of
canine endothelial cells infected with Adex1CAhtPA (lane
1) and Adex1CALacZ (lane 2) and noninfected canine
endothelial cells (lane 3) was isolated, electrophoresed, and
hybridized with a radiolabeled human tPA RNA probe, as
described in the Methods section. The β-actin control
bands are shown below. Human tPA messenger RNA was
strongly expressed in human tPA-transduced cells, but no
signal was detected in β-galactosidase–transduced or non-
transduced endothelial cells. The β-actin messenger RNA
level was not different among the samples.
1000. At an MOI of 500, the levels of htPA antigen
and activity were 200.6 ± 50.5 ng/106 cells per 6
hours and 110.4 ± 20.1 IU/106 cells per 6 hours,
respectively. Both the htPA antigen and activity levels
were more than 40 times those produced by non-
transduced human ECs in vitro.10 No significant dif-
ference in cell density was observed for these MOI
values (data not shown).
The effect of incubation time on in vitro
human tissue-type plasminogen activator secre-
tion after infection with Adex1CAhtPA. The level
of secreted htPA was maximal 4 days after infection
and decreased significantly thereafter (Fig 1, D).
The number of ECs did not change for 21 days after
infection (data not shown).
Northern blot analysis. Strong expression of
htPA messenger RNA (mRNA) in htPA-transduced
canine ECs was shown by means of Northern blot
analysis, but htPA mRNA was not detected in LacZ-
transduced and nontransduced ECs. The levels of
the β-actin mRNA control were not significantly dif-
ferent among the samples (Fig 2).
In vivo flow study. Triplicate assays were per-
formed to examine the effect of mixing Adex1CAhtPA
with Adex1CALacZ on htPA production by trans-
duced ECs. ECs infected with Adex1CAhtPA alone
(at an MOI of 500) produced 200.6 ± 50.5 ng
htPA/106 cells per 6 hours, whereas ECs infected with
Adex1CAhtPA and Adex1CALacZ (at MOI of 500
each) both produced 210.3 ± 22.2 ng htPA/106 cells
per 6 hours. No significant difference in htPA secre-
tion was observed between these cells.
For the in vivo flow study, we implanted 16 seed-
ed ePTFE grafts bilaterally in the carotid arteries of
eight dogs. All the grafts except one were patent
when harvested 5 hours after implantation. Because
one LacZEC graft was thrombosed, we analyzed 14
grafts from the remaining seven dogs. A significant
reduction in carotid artery blood flow was observed
in all dogs immediately after implantation, but by
the time the graft was harvested, the blood flow had
returned to the level observed before implantation.
The average blood flow of the htPAEC and LacZEC
grafts at harvest was not significantly different
(156.9 ± 17.0 mL/min and 148.9 ± 16.9 mL/min,
respectively).
A representative example of htPAEC grafts
stained with X-gal solution (preimplantation and
postharvest) is presented in Fig 3. Before implanta-
tion, ECs were found at confluence on the graft, but
after harvest, the graft showed patchy defects in
ECs, most of which were covered with mural throm-
bi. A similar finding was observed in the other
implanted grafts, irrespective of whether the seeded
cells were htPAEC or LacZEC.
The systemic plasma fibrinogen level did not
change in the course of the study, and htPA antigen
could not be detected in the plasma of dogs. Among
seven dogs, the percentage cell retention on the
htPAEC and LacZEC grafts was 29.3% ± 8.7% and
19.5% ± 3.6%, respectively, and showed no signifi-
cant difference (Fig 4). htPA antigen was detected in
the culture medium of four harvested htPAEC
grafts. A positive relationship was found between
htPA antigen level and the retained cell number of
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Fig 3. Photomicrographs showing the typical appearance
of a human tissue-type plasminogen activator endothelial
cell (htPAEC) graft, stained with X-gal before implanta-
tion (A) and after harvest (B). The cells were seeded at a
confluent density on the graft, and the seeded grafts were
incubated for 24 hours before implantation. The grafts
were surgically implanted into the carotid arteries and
exposed to blood flow for 5 hours before harvest. The
preimplanted graft shows confluent endothelial cell seed-
ing (A), and the harvested graft shows patchy defects in
endothelial cells and an attached mural thrombus (B). In
situ cell counts for representative fields were performed, as
described in the Methods section, to determine the pro-
portion of cells retained on the graft. Original magnifica-
tion, 20× (A) and 10× (B).
A
B
harvested htPAEC grafts (Fig 5). This result shows
that secreted htPA is detectable when the cell densi-
ty is higher, suggesting that the genetically trans-
duced ECs produced the target protein in vivo.
We retrospectively analyzed each canine experi-
ment to determine which factors contributed to EC
retention on the grafts after in vivo exposure to
blood flow. There was no significant correlation
between cell retention and the amount of secreted
htPA or the level of blood flow (data not shown).
Although no correlation was observed between EC
retention on the graft in vivo and the number of
days of cell culture in vitro, there was a moderate,
but significant, negative correlation between EC
passage level and EC retention in vivo when
htPAEC and LacZEC were taken together (P =
.041, r = –.40; Fig. 6).
DISCUSSION
A new method of estimating endothelial cell
retention on grafts. To determine the retention of
tPA-transduced ECs seeded onto grafts, Huber et
al16 labeled ECs with 125I and compared the
radioactivity of a nonimplanted graft with that of an
implanted graft. Dunn et al13 compared tPA antigen
level secreted from seeded grafts that were not
exposed to flow with that of corresponding flow-
exposed grafts.
We coinfected ECs with Adex1CAhtPA and
Adex1CALacZ to directly visualize htPA-transduced
ECs, because LacZ-transduced cells can be stained
blue histochemically. This method could be adopted
to determine cell retention, because adenoviruses can
easily attain a very high transduction efficiency, as
compared with retroviruses. With the use of this his-
tochemical method, the “blue-stained” ECs, which
expressed the LacZ gene, were randomly transduced
with the htPA gene at the same time they were coin-
fected with Adex1CAhtPA and Adex1CALacZ (at an
MOI of 500 each). When we compared the retention
of the “blue-stained” cells after coinfection with the
retention of “blue-stained” cells after Adex1CALacZ
infection alone, we were able to analyze the effect of
increased tPA secretion on cell retention on the graft.
In addition, we were not only able to estimate the
cell density, but also morphologically analyze the
luminal surface of the graft, even after graft implan-
tation. We believe this method is more direct and
accurate for determining cell retention than those
described by other authors.13,16
To examine the effect of mixing Adex1CAhtPA
with Adex1CALacZ on htPA production by the
transduced ECs, we compared the level of htPA anti-
gen secreted from ECs infected with Adex1CAhtPA
at an MOI of 500 alone with that secreted by ECs
infected with Adex1CAhtPA and Adex1CALacZ at
an MOI of 500 each. We found no significant differ-
ence in htPA production between these ECs, sug-
gesting that infection with Adex1CALacZ at an MOI
of 500 had no effect on htPA production of the
transduced ECs. In addition, we infected htPAEC
and LacZEC with the same MOI of adenovirus (ie,
an MOI of 1000) to exclude a nonspecific effect of
adenoviral infection on cell viability and in vivo cell
retention.
The effect of tissue-type plasminogen activa-
tor on endothelial cell retention on a graft.
Huber et al16 reported that htPA-transduced ECs
adhered to grafts at a significantly lower rate (64% ±
2.1%) than nontransduced ECs (73.7% ± 4.1%) after
in vivo exposure to blood flow. Dunn et al13 report-
ed in their in vivo flow study that htPA-transduced
ECs were retained at a level as low as 0%, which was
significantly lower than the retention level of LacZ-
transduced ECs (32%). Both reports listed many
possible mechanisms responsible for the decreased
adherence of tPA-transduced ECs, including the
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Fig 4. In vivo retention of seeded endothelial cells. After
5 hours exposure to in vivo blood flow, human tissue-type
plasminogen activator endothelial cell (htPAEC) and β-
galactosidase endothelial cell (LacZEC) grafts were fixed
and stained, and cell retention on the grafts was estimat-
ed, as described in the Methods section. No significant
difference in cell retention was observed between htPAEC
and LacZEC grafts. Data are presented as the mean plus
or minus the SEM. Each triangle represents an individual
graft.
proteolytic effect of tPA gene expression, the pas-
sage number of seeded ECs, and retrovirus-induced
inflammatory or immune responses.13,16
We measured both htPA antigen and activity to
demonstrate that htPAECs secrete a large amount of
functional htPA. It has been demonstrated that htPA
is efficient also in thrombolysis in dogs.17 Thus, our
canine model is a suitable means of examining the
effects of functional tPA on cell retention in vivo.
Although a much higher level of htPA antigen was
achieved in adenovirally transduced canine ECs, we
observed no significant difference in the level of cell
retention in vivo between htPAEC grafts (29.3% ±
8.7%) and LacZEC grafts (19.5% ± 3.6%). In addi-
tion, we used only early-passage ECs (passage 3 to 6),
whereas Dunn et al13 passaged ECs between five and
14 times. It has been reported that decreased reten-
tion in vivo of transduced ECs correlates with the EC
passage number,13 as was also observed in the present
study. These findings may suggest that tPA overex-
pression has little effect on cell adhesion shortly after
transduction, when the ECs are at an early passage
number. Viral gene transfer and expression may alter
the integrity and function of transduced ECs.
Retrovirus-mediated transduction has been shown to
impair proliferation of the transduced ECs, especially
in the late passages in vitro,18 and to induce a signifi-
cant decrease in the retention of the transduced ECs,
as compared with nontransduced ECs.19 Similar
responses could be present during adenoviral gene
transduction. Indeed, low-level gene expression of
adenoviral vectors generates cellular immune respons-
es that lead to destruction of the transduced cells.20
Our results with htPA secretion from the harvest-
ed grafts suggest that genetically transduced ECs
express the target protein in vivo, but the levels of
cell retention were relatively low, irrespective of the
gene used to transduce the ECs. It should be noted
that low EC retention was seen in in vivo studies for
a short period with ECs on ePTFE grafts.13 At least,
the low EC retention was not caused by surgical
manipulation, because all the procedures during graft
implantation were performed with minimal touching
of the graft and because we observed no cell loss by
comparing the cell density on the edge of the graft
just before implantation with that of the other edge
after completion of the proximal anastomosis.
We could not detect circulating htPA antigen in
the canine plasma, even when htPAEC grafts were
implanted. A considerable amount of tPA, produced
locally, directly binds to fibrin as a thrombolytic agent,
and tPA is soon inactivated by plasminogen activator
inhibitor 1. Even when tPA converts plasminogen to
the active protease plasmin in the presence of fibrin,
plasmin is immediately inactivated by α2 plasmin
inhibitor. We consider tPA to be efficient only at the
luminal surface of the graft, where ECs are seeded.
Therefore, there is very little possibility that circulat-
ing htPA is detectable in the canine plasma and that
the recombinant htPA secreted from htPAEC grafts
has a proteolytic effect on the contralateral graft.
According to previous studies of in vitro reten-
tion of nontransduced ECs seeded onto grafts,21,22
the highest levels of retention were achieved when
the cells were seeded at full confluence and when the
graft was exposed to flow 24 hours after seeding.
Recently, Dardik et al reported that in vivo retention
of genetically modified ECs was improved when
seeded grafts were treated with shear stress for sev-
eral days in vitro before implantation. Other coating
materials or graft materials could be adopted to pro-
duce tighter adhesion of ECs to the graft. In an in
vitro study, collagen-coated knitted Dacron showed
better retention of seeded ECs than ePTFE grafts
coated with human fibronectin.22 Gosselin et al24
exposed ePTFE grafts coated with fibronectin or 
fibrin glue containing fibroblast growth factor-1 and
heparin (FG/FGF-1/heparin) to ex vivo perfusion
and obtained cell retention rates of 85% and 96%,
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Fig 5. Human tissue-type plasminogen activator (htPA)
antigen secretion by harvested htPA endothelial cell
(htPAEC) grafts. A 1-cm segment of the harvested graft
was incubated for 6 hours in 1 mL culture medium, and
the supernatant was assayed for htPA. htPA antigen secre-
tion was detected in four of seven grafts assayed. Each tri-
angle represents an individual graft.
respectively. Thus, we may attain better cell reten-
tion in vivo if we select optimal graft materials, pre-
coating, and seeding conditions.
Adenoviral gene transfer. In recent studies
involving genetically modified ECs, retroviral trans-
duction has been widely used as a means of gene 
transduction.8,13,16,25,26 Compared with retroviral
transduction, however, adenoviral vectors have several
advantages: high transduction efficiency, high vector
titers, and the ability to infect nonreplicating cells and
tissues in situ.27,28 We were able to attain a transduc-
tion efficiency of 75% in early passage canine ECs with
adenoviral vectors. The htPA-transduced canine ECs
(htPAEC) produced approximately 200 ng htPA/106
cells per 6 hours, which is 40 times that secreted by
nontransduced human ECs. This high tPA level is sat-
isfactory for the purpose of the current study (that is,
to assess the short-term effect of a large amount of tPA
on EC retention on the surface of vascular prostheses).
In our study, the percentage of cell staining
increased, whereas the levels of htPA antigen and
activity increased very little, at an MOI between 500
and 1000 (Fig 1). One hypothesis to explain this dis-
crepancy is that the transduction efficiency is differ-
ent between the two adenoviruses, especially at a
high MOI. If the transduction efficiency of
Adex1CAhtPA is nearly 100% at an MOI of 500,
htPA production might increase very little between
an MOI of 500 and an MOI of 1000. Similar corre-
lations were observed between MOI and the htPA
antigen or cell-staining rate in human ECs.10
In dogs, 75% of ECs were transduced with
Adex1CALacZ at an MOI of 1000 (LacZEC),
whereas the transduction efficiency of human ECs
was nearly 90% at an MOI of only 30.10 This find-
ing, with other reports,29-31 suggests that the effi-
ciency of adenoviral gene transfer depends not only
on its absolute concentration, but also on the type of
the target cells and the type of experimental animals.
Adenoviral vectors have several important limita-
tions. Adenoviral gene expression is transient and
associated with inflammation of the target organs.32
htPA production by adenovirally transduced ECs
gradually decreased in vitro 4 days after infection
(Fig 1, D). In vivo, adenoviral gene expression
sharply declines approximately 1 week after trans-
duction.33 The short duration of expression of a for-
eign gene transferred by an adenovirus is critical for
its clinical efficacy. For clinical application, we need
a vector with higher efficiency and longer duration
of gene expression. However, recombinant htPA
produced by the htPA-transduced canine ECs was
detectable even 21 days after adenoviral infection
(Fig 1, D). Because as many as 23% to 45% of graft
failures occur within 1 month of distal bypass graft-
ing,34,35 antithrombotic grafts seeded with adenovi-
rally transduced ECs might be useful.
Conclusion. We confirmed that htPA can be
secreted, in vitro and in vivo, from canine ECs after
adenoviral transfer of the htPA gene. No significant
difference in cell retention was seen between htPA-
and LacZ-transduced ECs after in vivo exposure to
blood flow, which is contrary to the results of previous
studies with genetically modified ECs.13,16 Our data
may indicate that tPA overexpression has little effect
on the short-term retention of early-passage ECs seed-
ed onto grafts. However, further investigation is need-
ed to determine the factors, aside from cellular passage
number, that contribute to the low retention in vivo of
genetically modified ECs. We hope this study has pro-
vided information that will be useful in the future for
the production of antithrombotic prosthetic grafts.
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Fig 6. Correlation between endothelial cell retention in
vivo and cell passage number. After 5 hours of exposure to
in vivo blood flow, the retention of human tissue-type
plasminogen activator endothelial cell (htPAEC) and β-
galactosidase endothelial cell (LacZEC) seeded on grafts
was estimated, as described in the Methods section. Each
closed triangle and open rhombus represent an htPAEC
graft and a LacZEC graft, respectively. There was no neg-
ative correlation between cell passage number and in vivo
retention of htPAEC or LacZEC (n = 7; P = .11 and P =
.18, respectively). However, when the data for both types
of endothelial cells were combined, a moderate but signif-
icant negative correlation was observed between in vivo
retention and in vitro cell passage number (P = .041; r =
–.40). 
We thank Impra (Tempe, Ariz) for providing graft
materials and Dr N. Hoda for providing tPAEV37.
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